Stem Cell Boost Reinfusion

The patient is a 64-year-old female with a history of refractory secondary myelodyplastic syndrome that has evolved into secondary acute myelogenous leukemia (AML). She also has non-Hodgkin’s lymphoma. The patient was admitted for induction chemotherapy and consolidation chemotherapy with high dose Busulfan/Cyclophospamide using previously collected and purged cryopreserved autologous stems cells. During the hospitalization, her AML was treated with induction chemotherapy followed by consolidation chemotherapy and autologous peripheral blood stem cell boost reinfusion. When queried, the physician stated that the stem cell boost/reinfusion involves the infusion of extra stem cell product for patients that experience delayed or poor engraftment (blood count recovery) after the initial stem cell transplant. Although the stem cell boost is technically identical to the stem cell transplant, the stem cell boost is not the same because it does not entail both high dose chemotherapy and radiotherapy (conditioning phase). How should this be coded? ...

Subscribe or sign in to view the full article.

articles:   
Note:  The following article synopsis was NOT provided by the AHA. It was created by Find-A-Code/innoviHealth.

Article Overview

This article addresses coding-related interpretation of a stem cell boost/reinfusion scenario in a patient treated for hematologic malignancy. It provides context around transplant-related care, chemotherapy, engraftment issues, and how the procedure is discussed in relation to autologous stem cell therapy. The content is relevant to coders, CDI professionals, and reimbursement staff working with oncology and transplant records.

Why This Topic Matters

Transplant-related services can be difficult to interpret when documentation describes related but distinct parts of care. Understanding the article helps readers recognize the clinical setting and the type of reporting guidance being discussed for stem cell reinfusion scenarios.

What You Will Learn

  • The clinical context in which a stem cell boost/reinfusion may occur
  • How transplant-related documentation is framed in hematology-oncology records
  • Which broad reporting considerations are discussed for autologous stem cell procedures
  • How engraftment-related terminology appears in transplant care narratives

Who Should Read This

  • Medical coders
  • CDI specialists
  • Billing staff
  • Revenue cycle professionals
  • Oncology documentation reviewers

Subscribe or sign in to view the full article.

articles:   
  • The official AHA publication for ICD-10-CM and ICD-10-PCS coding guidelines and advice
  • Current newsletters added each quarter
  • Full Archives - over 3100 articles
  • ALL years/issues back to 1984 organized by year and issue
  • Includes ICD-10-CM/PCS Articles since 2013
  • Fully searchable through Find-A-Code's Comprehensive Search
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles
  • View all the articles associated with any code, right from the code page!
Access to this feature is available in the following products:
  • AHA's Coding Clinic® - ICD-10-CM/PCS +Archives

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.

Aimee- AI -powered coding assistant - Try it now for Free Would you like Aimee - AI
to help you with this?